Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Liquidia Corp (LQDA)

Liquidia Corp (LQDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,119,641
  • Shares Outstanding, K 86,995
  • Annual Sales, $ 14,000 K
  • Annual Income, $ -130,390 K
  • EBIT $ -107 M
  • EBITDA $ -105 M
  • 60-Month Beta 0.48
  • Price/Sales 44.27
  • Price/Cash Flow N/A
  • Price/Book 125.29

Options Overview Details

View History
  • Implied Volatility 136.66% (+4.37%)
  • Historical Volatility 63.77%
  • IV Percentile 87%
  • IV Rank 67.01%
  • IV High 185.25% on 10/31/25
  • IV Low 37.96% on 01/23/25
  • Expected Move (DTE 5) 5.13 (14.29%)
  • Put/Call Vol Ratio 0.51
  • Today's Volume 70,482
  • Volume Avg (30-Day) 9,992
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 172,623
  • Open Int (30-Day) 165,718
  • Expected Range 30.73 to 40.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.08
  • Number of Estimates 5
  • High Estimate 0.29
  • Low Estimate -0.08
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +117.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.30 +22.39%
on 01/06/26
38.16 -6.03%
on 01/09/26
+1.82 (+5.35%)
since 12/09/25
3-Month
21.94 +63.45%
on 10/23/25
38.16 -6.03%
on 01/09/26
+11.61 (+47.88%)
since 10/09/25
52-Week
11.26 +218.47%
on 04/09/25
38.16 -6.03%
on 01/09/26
+23.40 (+187.80%)
since 01/08/25

Most Recent Stories

More News
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update

Estimated YUTREPIAâ„¢ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in...

LQDA : 35.86 (+12.91%)
Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference

MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare...

LQDA : 35.86 (+12.91%)
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases,...

LQDA : 35.86 (+12.91%)
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Recorded $51.7 million in net product sales of YUTREPIAâ„¢ as launch momentum continues Achieved profitability in the first full quarter of YUTREPIA sales More than 2,000 unique patient prescriptions...

LQDA : 35.86 (+12.91%)
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced...

LQDA : 35.86 (+12.91%)
Bank of America Securities Sticks to Their Buy Rating for Liquidia Technologies (LQDA)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Liquidia Technologies, with a price target of $37.00. The company’s shares closed yesterday at $24.08.Elevate...

LQDA : 35.86 (+12.91%)
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025

MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today...

LQDA : 35.86 (+12.91%)
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting

MORRISVILLE, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced...

LQDA : 35.86 (+12.91%)
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium

MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease,...

LQDA : 35.86 (+12.91%)
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference

MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the...

LQDA : 35.86 (+12.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Liquidia Corporation is a biopharmaceutical company. It develops, manufactures and commercializes products for unmet patient needs principally in the United States. Liquidia Corporation, formerly known as LIQUIDIA TECHNL, is based in Morrisville, North Carolina.

See More

Key Turning Points

3rd Resistance Point 48.29
2nd Resistance Point 43.23
1st Resistance Point 39.54
Last Price 35.86
1st Support Level 30.79
2nd Support Level 25.73
3rd Support Level 22.04

See More

52-Week High 38.16
Last Price 35.86
Fibonacci 61.8% 27.88
Fibonacci 50% 24.71
Fibonacci 38.2% 21.54
52-Week Low 11.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar